Leslie WD, Morin SN, Lix LM, et al. - Since increased fracture risk has been reported in relation to aromatase inhibitors (AI) use in breast cancer, researchers, using a population-based registry for the Province of Manitoba, Canada, intended to assess the use of FRAX in women treated with AI. Participants were 1,775 women aged ≥ 40 years starting AI for breast cancer with at least 12 months’ AI exposure, 1,016 women with breast cancer not taking AI, and 34,205 women from the general population. In comparison with non-users, stratification for fracture risk among women receiving AI therapy was done equally well when using FRAX scores. However, overestimation of fracture risk happened when secondary osteoporosis was included as a risk factor for AI users. The findings call this practice into question.